Logo

Quark Delayed Graft Function Drug Safe in Phase I

May 06, 2010
Premium

Quark Pharmaceuticals this week announced the release of phase I data showing its delayed graft function prophylaxis QPI-1002 to be safe in kidney transplant recipients.

QPI-1002, which is designed to silence p53, was tested in 40 transplant recipients of kidneys from deceased donors. Safety data show no dose-limiting toxicities in any cohort, Quark said, supporting the drug's continued development.

The full data from the study are currently under analysis, the company added.

Filed under

Gene Silencing/Gene Editing
Disease Areas
RNAi
siRNA
Quark
delayed graft function
Breaking News
The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.